# Gujarat Themis Biosyn share price today (Gujarat Themis Biosyn Ltd, NSE: GUJTHEM)

> Gujarat Themis Biosyn share price today: ₹377.15 at the NSE close on 3 November 2026, down 18.6% in a year. Gujarat Themis Biosyn (NSE: GUJTHEM) is worth ₹4,911 crore, trades at a P/E of 100.9 and has closed between ₹251.50 and ₹450.25 over the past 52 weeks. > Gujarat Themis Biosyn Ltd's share price has fallen more than its earnings. Earnings per share fell 4.5% in a year while the price moved −18.6%. GUJTHEM · Pharma - API · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/gujarat-themis-biosyn-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting better, from the last 12 quarters
- Price: ₹377.15 (−18.6% in a year)
- P/E: 100.9× (higher than 98% of the last 11 years)
- Revenue (Jun 2026): ₹44.0 Cr (+22.2% on a year ago)
- Profit (Jun 2026): ₹11.0 Cr (+22.2% on a year ago)
- Operating margin: 48.0% (+9.0 points on a year ago)
- ROCE: 18%, FY26
- ROIC: 11.4%, against a 12.0% cost of capital: −0.6 points

The main question: results are strong, and the P/E is higher than 98% of its own history. ## What is the Gujarat Themis Biosyn share price today? Gujarat Themis Biosyn Ltd's share price was ₹377.15 at the close on 3 November 2026. It has been rising for 21 weeks. That is 1.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹252 and ₹450, and at that close it sat 63% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 2 weeks in a row. Over the last 11 years the share price moved +4,895% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Gujarat Themis Biosyn this quarter? Three changes stood out: profit grew again in the June 2026 quarter, operating margin up 9 points on a year earlier and revenue up on a year earlier for 4 quarters in a row. 1. Profit grew again in the June 2026 quarter Profit was ₹11 crore, +22.2% on a year earlier (₹9 crore), after 2 quarters of decline. Why: Profit rose because the company sold more product. Management pointed to sales volume as the quarter's main driver. Next results: check whether expanded fermentation capacity starts adding output. From the earnings call on 10 Aug 2026. 2. Operating margin up 9 points on a year earlier 48% in the June 2026 quarter, from 39%. 3. Revenue up on a year earlier for 4 quarters in a row In the June 2026 quarter revenue was ₹44 crore, +22.2% on a year earlier. Why: The company sold more product. Management said sales volume drove the quarter. Next results: check whether new fermentation supply wins sales beyond current customers. From the earnings call on 10 Aug 2026. ## What are Gujarat Themis Biosyn's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Gujarat Themis Biosyn reported revenue of ₹44.0 crore, up 22.2% from ₹36.0 crore a year earlier, and a profit of ₹11.0 crore, up 22.2% from ₹9.00 crore. ### Gujarat Themis Biosyn results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹44.0 crore | ₹36.0 crore | +22.2% |
| Profit | ₹11.0 crore | ₹9.00 crore | +22.2% |
| Earnings per share | ₹1.02 | ₹0.83 | +22.9% |
| Operating margin | 48.0% | 39.0% | +9.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Gujarat Themis Biosyn's management discussed these results on a call held on 10 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Gujarat Themis Biosyn share price history? Gujarat Themis Biosyn closed at ₹377.15 on 3 November 2026, down 18.6% from ₹463.05 a year earlier (31 October 2025) and up 408.4% over five years. Its highest weekly close since March 2016 was ₹463.05 on 31 October 2025. ### Gujarat Themis Biosyn share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹327.25 | +15.2% |
| 1 month ago · 1 Oct 2026 | ₹382.35 | −1.4% |
| 6 months ago · 30 Apr 2026 | ₹363.75 | +3.7% |
| 1 year ago · 31 Oct 2025 | ₹463.05 | −18.6% |
| 3 years ago · 3 Nov 2023 | ₹144.90 | +160.3% |
| 5 years ago · 4 Nov 2021 | ₹74.18 | +408.4% |
| 10 years ago · 4 Nov 2016 | ₹7.19 | +5,145.5% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹7.55 | +4,895.4% |
| Highest weekly close since March 2016 · 31 Oct 2025 | ₹463.05 | −18.6% |
| Lowest weekly close since March 2016 · 22 Feb 2019 | ₹3.91 | +9,545.8% |
| 52-week high (weekly close) · 7 Nov 2025 | ₹450.25 | −16.2% |
| 52-week low (weekly close) · 2 Apr 2026 | ₹251.50 | +50.0% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (564 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Gujarat Themis Biosyn? 3 Nov 2026: Gujarat Themis Biosyn closed at ₹377.15, up 15.2% on the week and down 1.4% on the month. 23 Sep 2026: ex-date for a dividend of ₹0.67 a share. ### Earlier

- 10 Aug 2026: Gujarat Themis Biosyn held its results call for April to June 2026. Management guided: Microbiopharm Japan funding described as largely in place; closing planned by end-August, equity up to ₹1,000 crore and final debt-equity mix open. - Results for April to June 2026: Revenue up 22.2% and profit up 22.2% on a year earlier. ## What dividend does Gujarat Themis Biosyn pay? Gujarat Themis Biosyn paid ₹0.67 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.18% at the ₹377.15 close on 3 November 2026. The last was a dividend of ₹0.67 a share, ex-date 23 September 2026. ### Gujarat Themis Biosyn dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 23 Sep 2026 | ₹0.67 | Dividend | same day |
| 4 Sep 2025 | ₹0.67 | Dividend | 5 Sep 2025 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 1 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Gujarat Themis Biosyn Ltd paid out 16% of its profit as dividends in FY26, and it paid a dividend in 6 of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Gujarat Themis Biosyn management say on the latest results call? On the call for April to June 2026, held on 10 August 2026, Gujarat Themis Biosyn's management guided: Microbiopharm Japan funding described as largely in place; closing planned by end-August, equity up to ₹1,000 crore and final debt-equity mix open. > “We are not entering any geography or business where we are taking responsibility for turning the business around.”
> Dr. Sachin Patel, on the call for April to June 2026

### What management guided

- Sanofi portfolio closing expected 6-9 months away, with June long-stop; country-by-country transfers begin after close and full manufacturing migration capped at 3 years. - Expanded fermentation capacity fully operational by quarter-end; output begins this quarter and builds in the second half. - Hybrid power Phase 1 go-live in September and Phase 2 two months later, improving operating margin through lower power cost. - FY27 base-business capital spending, including maintenance, around ₹15-20 crore; eligible new fermentation/API assets aiming for 1.4-1.5x asset turns on ₹200 crore of spending. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/901/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 10 August 2026.)

## What to watch in Gujarat Themis Biosyn's next results? When Gujarat Themis Biosyn reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Acquisition execution - check MBJ completion and funding structure, plus Sanofi regulatory progress against the stated closing window. - What to check (from the call)
- Acquisition execution - check MBJ completion and funding structure, plus Sanofi regulatory progress against the stated closing window. - Fermentation/API ramp - check first standalone contribution and whether incremental supply broadens sales beyond incumbent customer commitments. - Hybrid power commissioning - check phased go-live and evidence that lower electricity cost reaches operating profit. - Promoter encumbrance - check tangible releases or refinancing actions rather than only a stated reduction expectation. ## Which stock lists is Gujarat Themis Biosyn on? Gujarat Themis Biosyn is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 4810.945897577092](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Gujarat Themis Biosyn profitable? Gujarat Themis Biosyn Ltd earned ₹11.0 Cr of net profit in the Jun 2026 quarter, +22.2% on the same quarter a year earlier. Full-year FY26 profit was ₹47.0 Cr. Over 10 years profit has grown 25.1% a year on average. That is 25.0% of the quarter's revenue. The same quarter a year earlier earned ₹9.0 Cr. For the full year, FY26 profit was ₹47.0 Cr (−4.1% on the year before). Why profit moved: revenue changed +22.2% on a year earlier and the margin moved +9.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +8.4% and revenue +16.4%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Gujarat Themis Biosyn make, and is it growing? Gujarat Themis Biosyn Ltd reported ₹44.0 Cr of revenue in the Jun 2026 quarter, +22.2% on the same quarter a year earlier. That is the 4th quarter in a row with growth on the year before. Over 10 years it has grown 17.5% a year on average. The last full year, FY26, came in at ₹166 Cr. The last four reported quarters add to ₹173 Cr. FY26 revenue was ₹166 Cr, +9.9% on the year before. Recent pace: the last four quarters grew +16.4% on average, against 17.5% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +16.1%, against +4.0% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +6.7%, against −6.6% a year (accelerating). ## How much of every ₹100 of sales does Gujarat Themis Biosyn keep? Gujarat Themis Biosyn Ltd's operating margin was 48.0% in the Jun 2026 quarter, 9.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 16.0% and 51.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +8.7 percentage points on the year while gross margin changed +9.2 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Gujarat Themis Biosyn's profit turning into cash? Over the last 3 years, 132% of Gujarat Themis Biosyn Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹49.0 Cr of operating cash against ₹47.0 Cr of profit. After ₹198 Cr of spending on assets, free cash was −₹149 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 132% of profit came in as cash: the cash cycle got 347 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 17.2× depreciation over three years. The next section checks what that spending is building. ## Where does Gujarat Themis Biosyn's cash go? Gujarat Themis Biosyn Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −228 days in FY26, down from 119 days in FY21. It spent ₹378 Cr on assets over the last 3 years. Customers take 134 days to pay, and stock sits for 263 days on average. At FY26 sales of ₹166 Cr, each day of that cycle ties up about ₹0.5 Cr, so roughly −₹104 Cr is tied up in the business at any time. FY26: customers took 134 days to pay and stock sat for 263 days, about 8.7 months of sales sitting as stock, for a full cycle of −228 days, shorter than FY21's 119. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 263 days. Customers pay about 134 days after that. Suppliers are paid at 625 days. Together that makes the −228-day cycle. Spending on assets: ₹378 Cr over the last 3 years, against ₹22.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹121 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Gujarat Themis Biosyn's P/E ratio, and how does it compare with its own history? Gujarat Themis Biosyn Ltd's P/E is 100.9×, about the highest it has ever been. Its usual P/E (the middle reading) is 17.0×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹4.47. Why the multiple is where it is: over the past year earnings per share moved −4.5% while the price moved −18.6%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +38.4% a year; about +1.7% a year came from earnings growth and about +36.7 percentage points from the multiple (the market paying more); over 10 years the price moved +48.6% a year; about +25.0% a year came from earnings growth and about +23.6 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Gujarat Themis Biosyn business getting better or worse? Gujarat Themis Biosyn Ltd's business is getting better. Profit growth hit its low 4 quarters ago at −18.2% and has recovered to +6.7%, with ROCE falling at 19.9%. This is based on 12 quarters of 4 measures. Why it matters: a lasting rise from a low is what this page is built to show. ## How much does Gujarat Themis Biosyn earn on its capital? Gujarat Themis Biosyn Ltd earned a ROCE of 18% in FY26. Its return on capital used (ROIC) is 0.6 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 28.3% net margin and 0.33× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 28.3% net margin × 0.33× asset turnover × 1.75× leverage (assets divided by equity) ≈ 16.3% on equity. The margin does most of the work; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 11.4% − 12.0% = −0.6 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 11.4% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 13.2%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Gujarat Themis Biosyn have too much debt? Gujarat Themis Biosyn Ltd has total debt of ₹162 Cr against shareholder equity of ₹288 Cr as of Jun 2026, so its debt is 0.56× its equity. Year by year, that ratio went from 0.01 in FY22 to 0.56 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Gujarat Themis Biosyn shareholding pattern? Promoters cut their stake in Gujarat Themis Biosyn Ltd by 11.5 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 59.3% of the company. Domestic institutions moved +11.5 points over the same period, to 12.7%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −11.5 points over 8 quarters, to 59.3%; Domestic institutions: +11.5 points over 8 quarters, to 12.7%; Foreign institutions: +2.4 points over 8 quarters, to 3.8%. Why the owners changed: promoters drove it (−11.5 points), with the other side taken by domestic institutions (+11.5 points). They reduced their stake. ## How far is Gujarat Themis Biosyn from balance-sheet trouble? For Gujarat Themis Biosyn Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Gujarat Themis Biosyn rank in its industry? 55.2 out of 100, rank 7 of 14 in Pharma - API, with 89% of the evidence available. Gujarat Themis Biosyn Ltd scores 55.2 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 7. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 19.6 + 18.1 + 10.3 + 7.2 = 55.2. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Gujarat Themis Biosyn compared with? Gujarat Themis Biosyn ranks 7 of 14 Pharma - API companies on the 4-Factor Sector Score, with 55.2 out of 100. 1. [Anuh Pharma Ltd](https://www.sectoralpha.in/stocks/anuh-pharma-ltd) ANUHPHR · breaking out · Evidence leans up · 100% evidence 64.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 6.6% · Profit 23.7% · Operating margin change 3 points · 100% evidence Capital efficiency 13.8/25 · ROCE 14.9% · Operating margin 9% · 100% evidence Valuation 17.8/20 · P/E 18.3× · PEG 0.31 · 100% evidence Relative strength 11.5/20 · Lead over its industry -7.9% · Lead over NIFTY 500 14.5% · 1 year -3.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21.1 + 13.8 + 17.8 + 11.5 = 64.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Senores Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/senores-pharmaceuticals-ltd) SENORES · quiet · Evidence leans up · 75% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.2/35 · Revenue 38.9% · Profit 62.4% · Operating margin change -1 points · 95% evidence Capital efficiency 16.4/25 · ROCE 15.1% · Operating margin 30% · 76% evidence Valuation 9.2/20 · P/E 39.1× · PEG n/a · 15% evidence Relative strength 7.4/20 · Lead over its industry -6.3% · Lead over NIFTY 500 12.6% · 1 year 47% · 100% evidence · 7 of 12 weeks ahead Exact sum: 28.2 + 16.4 + 9.2 + 7.4 = 61.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Innova Captab Ltd](https://www.sectoralpha.in/stocks/innova-captab-ltd) INNOVACAP · leader · Evidence leans up · 96% evidence 60.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 34.4% · Profit 18.5% · Operating margin change 1 points · 88% evidence Capital efficiency 13.0/25 · ROCE 15% · Operating margin 16% · 100% evidence Valuation 7.3/20 · P/E 38.1× · PEG 4.06 · 100% evidence Relative strength 15.8/20 · Lead over its industry 3.4% · Lead over NIFTY 500 25.3% · 1 year 23.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24 + 13 + 7.3 + 15.8 = 60.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Beta Drugs Ltd](https://www.sectoralpha.in/stocks/beta-drugs-ltd) BETA · losing its lead · Evidence leans up · 67% evidence 56.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/35 · Revenue 15.3% · Profit 26.2% · Operating margin change 1 points · 95% evidence Capital efficiency 18.4/25 · ROCE 19.2% · Operating margin 22% · 76% evidence Valuation 8.0/20 · P/E 38.5× · PEG n/a · 50% evidence Relative strength 10.5/20 · Lead over its industry n/a · Lead over NIFTY 500 11.2% · 1 year -3.1% · 25% evidence · 8 of 12 weeks ahead Exact sum: 19.8 + 18.4 + 8 + 10.5 = 56.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Ind-Swift Laboratories Ltd](https://www.sectoralpha.in/stocks/ind-swift-laboratories-ltd) INDSWFTLAB · leader · Evidence leans up · 82% evidence 56.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 29.9% · Profit -64.1% · Operating margin change 14.3 points · 95% evidence Capital efficiency 8.3/25 · ROCE 4.9% · Operating margin 19% · 76% evidence Valuation 7.1/20 · P/E 34.9× · PEG n/a · 50% evidence Relative strength 20.0/20 · Lead over its industry 71.6% · Lead over NIFTY 500 98.2% · 1 year 257.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21 + 8.3 + 7.1 + 20 = 56.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Wanbury Ltd](https://www.sectoralpha.in/stocks/wanbury-ltd) WANBURY · quiet · Evidence leans up · 81% evidence 55.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.0/35 · Revenue 3.6% · Profit 30% · Operating margin change -5.2 points · 88% evidence Capital efficiency 16.6/25 · ROCE 30.7% · Operating margin 9.8% · 100% evidence Valuation 19.2/20 · P/E 11.2× · PEG 0.34 · 100% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -19.7% · 1 year -27.9% · 25% evidence · 0 of 12 weeks ahead Exact sum: 12 + 16.6 + 19.2 + 7.5 = 55.3 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 7. Gujarat Themis Biosyn Ltd this page GUJTHEM · turning · Evidence leans up · 89% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.6/35 · Revenue 16.1% · Profit 6.7% · Operating margin change 9 points · 88% evidence Capital efficiency 18.1/25 · ROCE 18.1% · Operating margin 48% · 100% evidence Valuation 10.3/20 · P/E 97.1× · PEG 1.33 · 65% evidence Relative strength 7.2/20 · Lead over its industry -16.3% · Lead over NIFTY 500 3.7% · 1 year -21.7% · 100% evidence · 5 of 12 weeks ahead Exact sum: 19.6 + 18.1 + 10.3 + 7.2 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Aarti Drugs Ltd](https://www.sectoralpha.in/stocks/aarti-drugs-ltd) AARTIDRUGS · turning · Evidence leans up · 96% evidence 50.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.5/35 · Revenue 10.5% · Profit 1.1% · Operating margin change 1 points · 88% evidence Capital efficiency 13.4/25 · ROCE 12% · Operating margin 14% · 100% evidence Valuation 8.2/20 · P/E 20.6× · PEG 3.2 · 100% evidence Relative strength 12.0/20 · Lead over its industry -6.8% · Lead over NIFTY 500 15.8% · 1 year -11.3% · 100% evidence · 9 of 12 weeks ahead Exact sum: 16.5 + 13.4 + 8.2 + 12 = 50.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Jagsonpal Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jagsonpal-pharmaceuticals-ltd) JAGSNPHARM · breaking out · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue 6% · Profit -27% · Operating margin change -1 points · 100% evidence Capital efficiency 19.1/25 · ROCE 22.7% · Operating margin 21% · 100% evidence Valuation 6.4/20 · P/E 30.2× · PEG 3.39 · 100% evidence Relative strength 6.4/20 · Lead over its industry -10.7% · Lead over NIFTY 500 9.9% · 1 year -2.7% · 100% evidence · 7 of 12 weeks ahead Exact sum: 14.6 + 19.1 + 6.4 + 6.4 = 46.5 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 10. [Aarti Pharmalabs Ltd](https://www.sectoralpha.in/stocks/aarti-pharmalabs-ltd) AARTIPHARM · breaking out · Evidence leans down · 85% evidence 44.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 13.4% · Profit 6.7% · Operating margin change 4 points · 100% evidence Capital efficiency 12.4/25 · ROCE 10.7% · Operating margin 22% · 100% evidence Valuation 2.9/20 · P/E 30.4× · PEG 5.52 · 100% evidence Relative strength 11.8/20 · Lead over its industry n/a · Lead over NIFTY 500 22.9% · 1 year 2.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 17.8 + 12.4 + 2.9 + 11.8 = 44.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Fermenta Biotech Ltd](https://www.sectoralpha.in/stocks/fermenta-biotech-ltd) FERMENTA · losing its lead · Evidence leans down · 64% evidence 42.8 out of 100 Growth Capital Valuation Relative
12. [Kopran Ltd](https://www.sectoralpha.in/stocks/kopran-ltd) KOPRAN · breaking out · Evidence leans down · 81% evidence 41.5 out of 100 Growth Capital Valuation Relative
13. [Orchid Pharma Ltd](https://www.sectoralpha.in/stocks/orchid-pharma-ltd) ORCHPHARMA · losing its lead · Evidence leans down · 66% evidence 37.8 out of 100 Growth Capital Valuation Relative
14. [Themis Medicare Ltd](https://www.sectoralpha.in/stocks/themis-medicare-ltd) THEMISMED · quiet · Most evidence points down · 71% evidence 30.1 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API](https://www.sectoralpha.in/sectors/pharma-api), all 14 compared on one page. ## Which companies are close to Gujarat Themis Biosyn in size? Gujarat Themis Biosyn is the 5th largest of 14 Pharma - API companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Innova Captab, Senores Pharmaceuticals and Orchid Pharma. Just below it: Aarti Drugs, Ind-Swift Laboratories and Beta Drugs. ### Pharma - API companies close in size

1. [Innova Captab Ltd](https://www.sectoralpha.in/stocks/innova-captab-ltd) ₹5,867 crore
2. [Senores Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/senores-pharmaceuticals-ltd) ₹5,222 crore
3. [Orchid Pharma Ltd](https://www.sectoralpha.in/stocks/orchid-pharma-ltd) ₹5,009 crore
4. Gujarat Themis Biosyn Ltd ₹4,727 crore
5. [Aarti Drugs Ltd](https://www.sectoralpha.in/stocks/aarti-drugs-ltd) ₹3,972 crore
6. [Ind-Swift Laboratories Ltd](https://www.sectoralpha.in/stocks/ind-swift-laboratories-ltd) ₹3,202 crore
7. [Beta Drugs Ltd](https://www.sectoralpha.in/stocks/beta-drugs-ltd) ₹2,000 crore

[All 14 Pharma - API companies, largest first](https://www.sectoralpha.in/sectors/pharma-api#all-companies)

### Companies close in size in other industries

1. [Ram Ratna Wires Ltd](https://www.sectoralpha.in/stocks/ram-ratna-wires-ltd) ₹4,734 crore · Copper Wires
2. [Aditya Birla Fashion & Retail Ltd](https://www.sectoralpha.in/stocks/aditya-birla-fashion-retail-ltd) ₹4,733 crore · Textiles - Readymade Apparel
3. Gujarat Themis Biosyn Ltd ₹4,727 crore
4. [SS Retail Ltd](https://www.sectoralpha.in/stocks/ss-retail-ltd) ₹4,726 crore
5. [PDS Ltd](https://www.sectoralpha.in/stocks/pds-ltd) ₹4,678 crore · Services - Others

## What else do people ask about Gujarat Themis Biosyn? ### What is Gujarat Themis Biosyn's share price today? Gujarat Themis Biosyn Ltd's share price is ₹377.15, −18.6% over the past year. The whole company is worth ₹4,911 Cr on the market. In the last 52 weeks it traded between ₹252 to ₹450; today it is 63% of the way up from the low, 1.4% above its 200-day average (as of 3 November 2026). ### What were Gujarat Themis Biosyn's latest quarterly results? Gujarat Themis Biosyn Ltd reported revenue of ₹44.0 Cr and net profit of ₹11.0 Cr for the Jun 2026 quarter. Revenue rose 22.2% and profit rose 22.2% compared with a year earlier. Earnings per share were ₹1.02. The operating margin was 48.0%, 9.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Gujarat Themis Biosyn's market cap? Gujarat Themis Biosyn Ltd's market capitalisation is ₹4,911 Cr at a share price of ₹377.15. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Gujarat Themis Biosyn performing? Gujarat Themis Biosyn Ltd's share price has been rising for 21 weeks. In its latest quarter, revenue rose 22.2% and profit rose 22.2% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 2 weeks running (as of 3 November 2026). ### Will Gujarat Themis Biosyn's share price go up? This page does not forecast Gujarat Themis Biosyn Ltd's share price. What it shows instead: the share price is ₹377.15, and it has been rising for 21 weeks. Its P/E of 100.9× is higher than 98% of its own last 11 years (as of 3 November 2026). ### Who owns Gujarat Themis Biosyn? Promoters own 59.3% of Gujarat Themis Biosyn Ltd, foreign institutions 3.8%, domestic institutions 12.7% and the public 24.2% (latest quarter). The biggest change over the last two years: Promoters cut their stake by 11.5 percentage points over 8 quarters (as of 3 November 2026). ### Where is Gujarat Themis Biosyn in its business cycle? Gujarat Themis Biosyn Ltd's FY26 operating margin was 46.0%, against a 13-year range of 16.0% to 51.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 48.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Gujarat Themis Biosyn story? The main question: results are strong, and the P/E is higher than 98% of its own history. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Gujarat Themis Biosyn a stock worth studying right now? What the numbers show: Gujarat Themis Biosyn Ltd's share price has fallen more than its earnings. Earnings per share fell 4.5% in a year while the price moved −18.6%. The main open question: whether earnings grow enough to match the multiple. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Gujarat Themis Biosyn share price forecast for 2026? What management itself guided: Microbiopharm Japan funding described as largely in place; closing planned by end-August, equity up to ₹1,000 crore and final debt-equity mix open. ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.